Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 839,994 shares, a growth of 77.3% from the July 15th total of 473,657 shares. Approximately 13.7% of the company’s stock are short sold. Based on an average daily volume of 24,575,177 shares, the short-interest ratio is currently 0.0 days.

Matinas Biopharma Stock Down 1.7%

Shares of Matinas Biopharma stock traded down $0.00 during midday trading on Monday, hitting $0.23. The company’s stock had a trading volume of 104,551 shares, compared to its average volume of 2,154,367. Matinas Biopharma has a 1-year low of $0.22 and a 1-year high of $2.24. The firm has a market capitalization of $1.47 million, a P/E ratio of -0.20 and a beta of 1.76. The stock has a 50-day simple moving average of $0.49 and a 200-day simple moving average of $0.57.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share for the quarter.

Hedge Funds Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC purchased a new position in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma at the end of the most recent reporting period. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical?stage biopharmaceutical company that specializes in the development of novel lipid?based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water?soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life?threatening fungal infections.